Low-dose ramosetron containing orally disintegrating tablet

The purpose of the present invention is to provide an orally disintegrating tablet which contains low-dose ramosetron or a pharmaceutically acceptable salt thereof and has biological equivalence to conventional tablets. Provided is an orally disintegrating tablet comprising ramosetron or a pharmaceutically acceptable salt thereof in an equivalent molar amount to 0.001 to 0.05 mg inclusive of ramosetron hydrochloride and an agar and/or an agar powder.